LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Pulmonary Pharmacology
- 1st Edition, Volume 98 - August 1, 2023
- Editor: W.S Fred Wong
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 8 8 0 - 0
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 8 8 1 - 7
Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include c… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthma, COPD or pulmonary fibrosis, with perspective on the development of novel therapeutic strategies such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Part of the volume is devoted to senotherapy for lung ageing in respiratory diseases, and novel pulmonary delivery technologies, including inhaled biologics.
- Provides accurate reviews from leading experts on the topic of pulmonary pharmacology
- Each chapter of the volume provides consolidated graphical materials for ease of reading for the audience
- Provides the latest insights and future perspectives on the drug discovery and development for respiratory diseases
Biomedical scientists, clinicians, and medicinal chemists in drug discovery and developing, pathophysiology or pharmaceutics, who are particularly interested in respiratory diseases such as asthma, COPD and pulmonary fibrosis
- Cover image
- Title page
- Table of Contents
- Advances in PHARMACOLOGY
- Copyright
- Contributors
- Preface
- Abbreviations
- Chapter One: Genomic and non-genomic effects of glucocorticoids in respiratory diseases
- Abstract
- Abbreviations
- 1 Introduction
- 2 Genomic mechanisms of action: GR activation
- 3 GR transactivation or transrepression-mediated mechanisms of action of GCs
- 4 Non-genomic mechanisms of action of GCs
- 5 Conclusion
- Acknowledgements
- References
- Chapter Two: Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment
- Abstract
- Abbreviation
- 1 Introduction
- 2 IL-5
- 3 Mepolizumab
- 4 Reslizumab
- 5 Benralizumab
- 6 IL-4 and IL-13
- 7 Dupilumab
- 8 Future developments
- 9 Conclusion
- Conflicts of interest
- References
- Chapter Three: Phosphodiesterase inhibitors and lung diseases
- Abstract
- Abbreviations
- 1 Introduction
- 2 Conclusion
- Conflict of interest statement
- References
- Chapter Four: Prospects for macrolide therapy of asthma and COPD
- Abstract
- Abbreviations
- 1 Introduction
- 2 Why asthma and COPD
- 3 What non-antimicrobial macrolide actions are relevant
- 4 Can antibiosis with macrolides be circumvented
- 5 Conclusion
- Acknowledgments
- References
- Note in proof
- Chapter Five: Targeting the renin angiotensin system for respiratory diseases
- Abstract
- Abbreviations
- 1 Introduction
- 2 Tareting renin angiotensin system in asthma
- 3 Targeting renin angiotensin system in COPD
- 4 Targeting renin angiotensin system in pulmonary fibrosis
- 5 Targeting renin angiotensin system in acute lung injury
- 6 Conclusion
- References
- Chapter Six: Progress in the development of kinase inhibitors for treating asthma and COPD
- Abstract
- Abbreviations
- 1 Introduction
- 2 Conclusion
- Conflict of interest statement
- References
- Chapter Seven: Anti-fibrotic strategies and pulmonary fibrosis
- Abstract
- Abbreviations
- 1 Introduction
- 2 IPF pathogenesis: Initiation of fibrogenesis
- 3 Pathways implicated in fibrosis
- 4 Growth factor and cytokine activation in IPF
- 5 Mechanotransduction and Hippo activation
- 6 Cellular players in IPF
- 7 IPF models
- 8 IPF drug treatment
- 9 Recommended drugs for IPF: Pirfenidone and nintedanib
- 10 Conclusion
- References
- Chapter Eight: Novel treatments against airway inflammation in COPD based on drug repurposing
- Abstract
- Abbreviations
- 1 Introduction
- 2 The novel pharmacologic targets
- 3 Conclusion
- Acknowledgements
- References
- Chapter Nine: Senotherapy for lung diseases
- Abstract
- Abbreviations
- 1 Introduction
- 2 Senotherapy for lung disease
- 3 Conclusion
- Conflict of interest
- References
- Chapter Ten: Delivery technology of inhaled therapy for asthma and COPD
- Abstract
- Abbreviations
- 1 Introduction
- 2 Inhaled therapy for asthma and COPD
- 3 Challenges and barriers of drug delivery to the lung
- 4 Aerosol drug delivery
- 5 Inhaler devices: their merits and limitations
- 6 Recent development – biologics for inhalation
- 7 Conclusion
- References
- No. of pages: 334
- Language: English
- Edition: 1
- Volume: 98
- Published: August 1, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443188800
- eBook ISBN: 9780443188817
WW
W.S Fred Wong
Dr. W.S. Fred Wong received his BPharm (with cum laude) from the St. Johns’ University in New York, and his PhD in Pharmacology from The Ohio State University in Columbus, Ohio. He moved to Lilly Research Laboratories at Indianapolis as a postdoctoral scientist with research focus on respiratory drug development and then to Respiratory and Critical Care Medicine Division at the Brigham and Women’s Hospital in Boston as a Research Fellow in Medicine. After that, Dr. Wong joined the Department of Pharmacology at The National University of Singapore (NUS) and since built the Respiratory Pharmacology Laboratory. Dr. Wong is a Professor of Pharmacology, former Head of the Department, and former Assistant Dean and Vice Dean of the Yong Loo Lin School of Medicine, National University of Singapore. He is the Director of the Drug Discovery and Optimization Platform (DDOP) in the Yong Loo Lin School of Medicine. He is the Principal Investigator of the Singapore-HUJ Alliance for Research and Enterprise (SHARE). Dr. Wong is the founding President of the Singapore Pharmacological Society. His research interest is to identify therapeutic targets and to discover and develop pharmacological agents for the treatment of airway inflammation, oxidative and DNA damage and remodeling in asthma and in COPD, using small molecule drugs, herbal medicinal bioactive molecules, antisense oligonucleotides (ASO)/siRNA technology, and pharmacoproteomics and metabolomics approaches. He has published a series of mechanism-based drug discovery studies targeting at tyrosine kinases, p38 MAPK, ERK1/2, PI3K, GSK-3, RIP2, RPS3 and AT2R responsible for asthma and COPD pathogenesis, that have paved the way for further investigation and innovative development of specific therapeutic strategies for asthma and COPD. Natural compounds like the diterpenoid lactone andrographolide and calcaratarin D, vitamin E isoform -tocotrienol, and anti-malarial drug artesunate were first reported by his laboratory to possess anti-inflammatory actions in both asthma and COPD. His laboratory has also identified lungkine, ApoL2 and house dust mite-induced DNA damage as potential mechanisms for asthma pathogenesis.
Affiliations and expertise
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of SingaporeRead Pulmonary Pharmacology on ScienceDirect